COMMUNIQUÉ DE PRESSE
News
-
-
COMMUNIQUÉ DE PRESSE
NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference
Nanobiotix announces presentation of data from two Phase 1 studies evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference. Studies highlight safety, efficacy, and collaboration strategies -
-
-
COMMUNIQUÉ DE PRESSE
NANOBIOTIX renforce sa visibilité financière en amendant son accord de licence globale pour JNJ-1900 (NBTXR3) qui étend son horizon de trésorerie jusqu’à mi-2026
Nanobiotix renforce sa visibilité financière en amendant son accord de licence avec JNJ-1900 (NBTXR3), étendant son horizon de trésorerie jusqu’à mi-2026. Conférence le 18/03/2025 -
COMMUNIQUÉ DE PRESSE
NANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-2026
Nanobiotix strengthens financial position by amending global licensing agreement for JNJ-1900 (NBTXR3), extending cash visibility to mid-2026. Details of the amendment and future potential milestone payments outlined -
-
-
-
